COMMON STOCK PURCHASE WARRANT NUO THERAPEUTICS, INC.Common Stock Purchase Warrant • August 30th, 2022 • Nuo Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
Contract Type FiledAugust 30th, 2022 Company Industry JurisdictionFor purposes of this paragraph, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (y) a more recent public announcement by the Company, or (z) a more recent written notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of the Holder, the Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the n
COMMON STOCK PURCHASE WARRANT NUO THERAPEUTICS, INC.Common Stock Purchase Warrant • August 30th, 2022 • Nuo Therapeutics, Inc. • Surgical & medical instruments & apparatus • Delaware
Contract Type FiledAugust 30th, 2022 Company Industry JurisdictionFor purposes of this paragraph, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (y) a more recent public announcement by the Company, or (z) a more recent written notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of the Holder, the Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the n